Pathogenic variants in KCNB1, encoding the voltage-gated potassium channel KV2.1, are associated with developmental and epileptic encephalopathies (DEE). Previous functional studies on a limited number of KCNB1 variants indicated a range of molecular mechanisms by which variants affect channel function, including loss of voltage sensitivity, loss of ion selectivity, and reduced cell-surface expression. We evaluated a series of 17 KCNB1 variants associated with DEE or neurodevelopmental disorder (NDD) to rapidly ascertain channel dysfunction using high-throughput functional assays.
INTRODUCTION
De novo variants in a diverse range of genes constitute a significant cause of developmental and epileptic encephalopathies (DEE) and other neurodevelopmental disorders (NDD) 1, 2 . Despite an increasing number of genes identified for DEE and increased implementation of clinical genetic testing, many variants remain variants of uncertain significance (VUS) that are difficult to interpret and/or act on. One powerful approach to bridge knowledge gap between the genetics and the molecular pathology is to obtain functional data 3 , which can then provide additional evidence for interpretation of variant pathogenicity and may offer information (e.g, loss-of-function vs. gain-of-function) to guide treatment strategies. However, due to the low throughput of many standard functional assays, functional annotation of variants has become a major bottleneck in the field. The development of high-throughput functional assays is a necessary step for the experimental validation of the large volume of novel variants being identified due to increasing clinical genetic testing. . Kcnb1-deficient mice display enhanced seizure susceptibility and behavioral hyperexcitability, indicating that KV2.1 acts as a homeostatic suppressor of heightened neuronal activity 6 . De novo missense variants of KCNB1 are associated with DEE [7] [8] [9] [10] [11] [12] [13] , which includes a wide spectrum of clinical phenotypes including multiple seizure types, developmental delay (DD), and neuropsychiatric sequelae. Correlational analyses based solely on the substituted amino acid type and position have proven insufficient for genotype-phenotype association 11 , highlighting the need for experimental studies to determine functional effects of additional variants. To date, seven KCNB1 variants associated with DEE, all located in the pore (S347R, T374I, V378A, G379R, G401R) and voltage-sensor (I199F, R306C) domains, have been shown to exhibit altered potassium current density, voltage-dependence, and/or ion selectivity [7] [8] [9] 14 . However, determining the functional consequences of a larger series of variants is necessary to define the full range of dysfunction and to broaden the range of associated clinical phenotypes studied.
In this study, we performed high-throughput functional studies of 19 KCNB1 variants (17 missense, 1 frameshift, 1 nonsense) in order to assess their effect on protein function and provide functional evidence for weighing potential pathogenicity. Several broad categories of channel dysfunction (i.e. altered peak current density, voltage-dependence, protein expression) were identified, and most of the examined variants confer some degree of loss-of-function. Our results provide insight into functional pathogenicity for a large series of KCNB1 variants. This will aid in prioritization for development of more complex experimental models (i.e. knock-in mouse or iPSC) by identifying a subset of representative variants based on underlying pathophysiologic mechanisms. Uncovering a range of KCNB1 functional defects will help define genotype-phenotype relationships by adding a molecular phenotype to the genotypes and may ultimately enable development of targeted treatment strategies for individuals with KCNB1 DEE.
MATERIALS AND METHODS

Study Subjects
Clinical and genetic information was retrospectively collected for individuals with DEE or global DD of unknown cause and a potentially pathogenic KCNB1 variant identified by clinical genetic testing as part of routine care. Clinical and genetic information was collected under approval of the Ann & Robert H. Lurie Children's Hospital of Chicago Institutional Review Board (IRB), the IRB of collaborating institutions, or through collection of de-identified medical information deemed non-human subjects research by the Northwestern University Institutional Review Board (IRB). Consent for release of deidentified information was obtained from the parents/guardians in accordance with local institutional policies. In addition, 11 KCNB1 variants were obtained from the literature [8] [9] [10] [11] [12] [13] 15, 16 and variant databases [17] [18] [19] . Functional studies had not been previously reported for 17 of the 19 variants described in this study.
Cell Culture
Chinese hamster ovary cells (CHO-K1, CRL 9618, American Type Culture Collection, Manassas VA, USA) were grown in F-12K nutrient mixture medium (GIBCO/Invitrogen, San Diego, CA, USA) supplemented with 10% fetal bovine serum (FBS, ATLANTA Biologicals, Norcross, GA, USA), penicillin (50 units·mL 
Plasmids
Full-length human wild-type KCNB1 (KV2.1) cDNA engineered in the plasmid pIRES2-DsRed-MST was previously described 7, 14 . Mutations were introduced by QuikChange mutagenesis (Agilent, Santa Clara, CA, USA) using pIRES2-DsRed-MST-KCNB1-WT as template. All recombinant cDNAs were sequenced in their entirety to confirm the presence of the desired modifications and the absence of unwanted mutations in the cDNA. Endotoxin-free plasmid DNA from sequence-verified clones was isolated using the Nucleobond Xtra Midi EF Kit (Macherey-Nagel, Düren Germany), ammonium acetate precipitated and re-suspended in MaxCyte buffer (MaxCyte Inc., Gaithersburg, MD, USA). For cotransfection experiments, pIRES2-DsRed-MST-KCNB1-WT was engineered to replace DsRed-MST with smGFP using Gibson assembly to generate pIRES2-smGFP-KCNB1-WT. For cell-surface labeling of KV2.1 proteins, a 2x tandem HA tag (YPYDVPDYAYPYDVPDYA) was inserted between phenylalanine 220 and glycine 221, followed by removal of downstream of IRES element and the reporter fluorophore, resulting in plasmid pCMV-KCNB1-HA-WT.
Heterologous Expression
Transient expression of wild-type (WT) and variant KCNB1 in CHO-K1 cells was achieved by electroporation using the Maxcyte STX (MaxCyte Inc.) system as per manufacturer instructions. Briefly, cells grown to 70-80% confluence were harvested using 0.25% trypsin-EDTA, washed once with electroporation buffer (EBR100; MaxCyte Inc.) and then re-suspended in the same buffer to a density of 100 × 10 6 viable cells/mL. For each electroporation, KCNB1 cDNA (7.5-10µg) was added to 100 µL of cell suspension and the mixture was transferred to an OC-100 (OC-100R10; MaxCyte Inc.) processing assembly, then electroporated using the preset CHO or CHO-PE (protein-expression) protocol.
Immediately after electroporation, 10 µL of DNaseI was added to DNA-cell suspension and the whole mixture was then transferred into a 60mm dish and incubated for 30 min at 37°C in 5% CO2. Following incubation, the cell suspension was gently re-suspended in culture media, transferred to a T75 tissue culture flask, and grown for 36 hours at 37°C in 5% CO2. After this period, cells were harvested and then frozen in liquid N2. Co-expression of WT and variant was achieved by co-electroporation of pIRES2-DsRed-MST-KCNB1-WT or -variant (5 µg) plus pIRES2-EGFP-KCNB1-WT (5 µg) using the same protocol.
Cell Preparation for Automated Patch Clamp Recording
Cells were thawed and incubated for 24 hours at 37°C in 5% CO2. Prior to the experiment, cells were harvested using 0.25% trypsin-EDTA in cell culture media. Cell aliquots were used to determine cell number and viability by automated cell counting (Vi-Cell, Beckman Coulter, Indianapolis, IN, USA).
Cells were diluted to a concentration of 200,000 total cells/mL with external solution (see below for composition) and then allowed to recover for 40 minutes at 15°C while shaking on a rotating platform at 200 rpm.
Automated Patch Clamp Recording
Automated patch clamp recording was performed using the SyncroPatch 768PE system (Nanion Technologies, Munich, Germany). The external solution contained (in mM): 140 NaCl, 4 KCl, 1 MgCl2, 2 CaCl2, 5 glucose, and 10 HEPES, pH 7.4. The internal solution contained (in mM): 60 KF, 50 KCl, 10 NaCl, 20 EGTA, 10 HEPES, pH 7.2. Pulse generation and data collection were done with PatchController 384 V1.3.0 and DataController384 V1.2.1 software (Nanion Technologies) and wholecell currents were acquired at 5 kHz and filtered at 1 kHz. Currents were not leak subtracted. Access resistance and apparent membrane capacitance were estimated using built-in protocols in the PatchController software. Whole-cell currents were measured at room temperature from a holding potential of -80 mV and elicited with depolarizing steps (500 ms) from -100 to +60 mV (10 mV steps) followed by a 250 ms step to -30 mV or 0 mV (tail currents). Background currents were removed by digital subtraction of whole-cell currents recorded from non-transfected CHO-K1 cells off-line. Current amplitudes were analyzed from all cells with seal resistance ≥0.5GΩ, series resistance ≤20MΩ and cell capacitance >2pF. Electrically unstable cells with loss of seal or voltage control during experiments were excluded from the analysis. The peak current was normalized for cell capacitance and plotted against voltage to generate peak current density-voltage relationships. Voltage-dependence of activation was determined by plotting tail currents normalized to the largest tail current amplitude against the depolarizing test potential (-100 to +60 mV). The normalized G-V curves were fit with the Boltzmann function: G = 1 / (1 + exp[(V-V½) / k] to determine the voltage for half-maximal channel activation (V½) and slope factor (k). The voltage-dependence of inactivation was assessed following a 5 s pre-pulse from -100 to +40 mV (10 mV steps) followed by a 250 ms step to +60 mV. The normalized peak currents measured at the +60 mV test potential were plotted against the pre-pulse voltage and fit with the 
Immunocytochemistry-Flow Cytometry
Cells were electroporated as described above and incubated for 24 hours at 37°C in 5% CO2 on 60mm For independent analyses of KV2.1 total protein expression (Fig. 3C&E) , frozen aliquots of cells electroporated as described above were thawed and cultured for 24 hours, and then directly harvested with Accutase, without the cell-surface protein labeling steps. Percent-positive variant-expressing cells (excited by 638nm laser) were normalized to WT-expressing cells tested on the same day. Histograms were aligned to correct for between-run variability in fluorescence intensity; y-axes were uniformly set at a maximum of 250 and 350 event counts (for Fig. C and E respectively) across conditions.
Cell Surface Biotinylation and Immunoblotting
Frozen aliquots of CHO-K1 cells electroporated with homotetramer WT or variant KCNB1 channels were thawed and grown under the same conditions used for automated patch clamp recording. Cell surface proteins were labeled with cell membrane impermeable Sulfo-NHS-Biotin (#21217, Thermo Blots were probed initially for transferrin receptor and calnexin in multiplex, followed by stripping with Restore Western Blot Stripping Buffer (21059, Thermo Fisher) and then reprobing for KV2.1. To control for protein loading, KV2.1 bands were normalized to the corresponding transferrin receptor band. Blots were imaged using the Odyssey CLx system (LI-COR, Lincoln, NE, USA) and densitometry was performed using ImageStudio software (LI-COR). Normalized total, surface, and surface/total protein ratio results were derived from 3 independent experiments. Calnexin immunoreactivity was present in total protein lysates and absent from the cell surface fraction, confirming the selectivity of biotin labeling for cell surface protein.
Data Analysis
Data were analyzed and plotted using a combination of DataController384 V1. Principal component analysis (PCA) was performed using ClustVis 20 , with principal components (PC) calculated using the non-linear iterative partial least square (Nipals) algorithm. A total of 6 dimensions from the homomeric condition were compared: Ipeak density, V1/2 and k for activation and inactivation, cell-surface/total expression ratio. Prior to PCA, data were normalized with respect to the WT by percentile value or Z-score.
Data availability
The data that support the findings of this study are available from the corresponding author, upon reasonable request.
RESULTS
KCNB1 Variant In Silico Analysis and Associated Clinical Phenotypes
KCNB1 is intolerant of variation, with increased constraint for missense variants and intolerance for loss-of-function variation 18 . Examination of missense single nucleotide variations (SNVs) in the gnomAD database 21, 22 reveals a paucity of missense SNVs within the voltage-sensor and pore domains of the KCNB1, whereas all pathogenic variants reported to date are clustered in these regions [7] [8] [9] [10] [11] [12] [13] [14] . The altered residues reported in this study all show a high degree of evolutionary conservation ( (Table 1) 26 .
Clinical phenotypes for the variants functionally characterized in this report are summarized in Table 1 , and include DEE in 28 patients and NDD in four patients. Among those with NDD, one had a single seizure and three had no history of seizure at last reported follow-up at 6 years of age or younger.
The phenotypes associated with novel variants reported in Table 1 are consistent with previous reports [7] [8] [9] [10] [11] [12] [13] [14] . Table 1 also includes variants from previous clinically focused reports 11, 16 , summarized here for completeness, with updates when available. In total, there are 17 pathogenic or likely pathogenic variants identified in 27 individuals. This includes a number of recurrent variants (T210M x3; R306C x6; R312C x2; R312H x2; E330D x 2; V378A x2; P385T x2; F416L x3), half of which occur at methylCpG dinucleotides that are known to be susceptible to deamination.
Functional consequences of K V 2.1 variants: I peak density
To screen for functional consequences of the missense or nonsense KCNB1 variants, we performed automated patch clamp recording of these variants expressed in CHO-K1 cells. Wild-type (WT) or variant KV2.1 channels were transiently transfected by electroporation and whole-cell currents recorded in voltage-clamp mode using the SyncroPatch 768PE automated patch clamp platform ( Fig. 2A) .
Previous studies have shown the feasibility of this approach to study channel properties of KV2.1 and the closely related KV7.1 channel encoded by KCNQ1 14, 27, 28 .
In addition, we also tested on this platform the T374I variant that we previously characterized by manual patch clamp recording 7 , and reproduced the loss-of-function phenotype ( Fig. 2B ; p < 0.001, unpaired t-test @ +60mV vs WT). This further validates use of this platform to screen for KV2.1 dysfunction.
The KV2.1 channel is composed of four alpha subunits encoded by KCNB1 that form a tetrameric assembly. When singly expressed in CHO cells, the KV2.1 channels assume a homomeric configuration consisting of 4 identical WT or variant subunits. In the homomeric configuration, the majority of the KV2.1 variants (13/19) exhibited low K + conductance (loss-of-function) (Fig. 3A, red bars) , while the remaining variants displayed moderate K + conductance (partial loss-of-function) (blue bars), or K+ conductance similar to WT (grey bars). The degree of loss-of-function was considered 'partial' if more than 50% reduction and 'severe' if more than 75% reduction in peak current density compared to WT.
The averaged whole-cell current density traces for KV2.1 WT and representative variants are displayed to show the diversity in peak current density (Fig. 3A right) . Averaged whole-cell current density traces for all KV2.1 variants are shown in supplementary Figure 1 . Averaged endogenous currents recorded from non-transfected CHO-K1 cells were digitally subtracted.
KCNB1 DEE is associated with de novo heterozygous variants. Thus, an individual has KV2.1 subunits produced from both WT and variant alleles. In order to determine the effect of the KCNB1 variants in a condition that resembles heterozygosity in the patient, we co-expressed each variant along with wild-type channels in a 1:1 equimolar ratio in CHO-K1 cells. In the co-expression configuration (WT+variant), many variants exhibited peak current density similar to cells transfected with WT+WT channels, suggesting that these variants may be rescued by WT co-expression. In contrast, the W370R, P385T and F416L variants exhibited significantly lower peak current density when compared to WT+WT cells (Fig. 3B, bars in red) . These variants also showed significantly lower peak current density when compared to cells transfected with half the amount of WT plasmid (0.5x WT), and suggest a dominant-negative interaction of the variant with WT subunits. The R306C and V378L variants exhibited a partial loss-of-function (bars in turquoise). Averaged current traces for a subset of variants are displayed (Fig. 3B right) 
Total protein expression of K V 2.1 variants
To test whether loss-of-function phenotypes, defined by impaired K + current density, was due to absence or reduction of channel protein, we evaluated total protein expression levels for KV2.1 variants using immunoblotting and/or immunocytochemistry-flow cytometry. Frozen aliquots of the same cells tested by electrophysiology above were used for this experiment. In the homomeric configuration, population analyses of KV2.1-positive cells confirmed that KCNB1 variants with severe loss-of-function phenotypes had lower levels of KV2.1 protein compared to WT (Fig. 3C&E) . The same variants when co-expressed 1:1 with WT showed similar results. Correlational analyses of peak current density and total protein expression of the variants showed no relationship between parameters in either the homomeric or coexpression condition ( Fig. 2A-C) .
Voltage-dependence of channel activation and inactivation
Voltage-dependence of channel activation and inactivation was assessed for the subset of KV2.1 variants with sufficient K + conductance to reliably measure these parameters. In the homomeric configuration, a subset of variants with K + conductance exhibited altered voltage-dependence of channel activation and inactivation when compared to the WT channel ( Table 2 ). The S202F and R312H variants exhibited substantial depolarizing shifts in their V1/2 for both channel activation and inactivation (Fig. 4A ) and significantly larger slope factors. This suggests a potential decrease in the sensitivity of channel inactivation to voltage change. The Y533X variant also induced a depolarizing shift in V1/2 of activation without affecting channel inactivation (Table 2 ). In contrast, the R325W variant caused hyperpolarizing shifts in the V1/2 values for both channel activation and inactivation (Fig. 4A) .
When co-expressed with WT, the effects of R312H on channel activation and inactivation were abolished, suggesting rescue by WT subunits. Co-expression with WT channels prevented the depolarizing shift in activation due to S202F. However, the observed differences in V1/2 and k inactivation for homomeric S202F channels were still present when co-expressed with WT channels (Table 2 ). The hyperpolarizing shifts in V1/2 for activation and inactivation caused by the R325W mutation were still present in the presence of WT subunits, albeit with smaller magnitude. Although the T210K variant was non-functional when expressed as homotetramer, it caused a hyperpolarizing shift in inactivation V1/2 when co-expressed with WT. Lastly, co-expression of WT and S457R channels resulted in a hyperpolarizing shift in V1/2 that was not observed for homomeric S457R channels (Table   2) . A complete statistical summary including V1/2 value and slope factor k for all variants is presented in Table 2 .
Functional effects of non-pathogenic variants
Two likely non-pathogenic variants (R325Q and S457R) were included in the functional assays, with the experimenters blinded to this status. The R325Q variant was reported as a singleton variant (MAF 3.983 e-06 ) in the genome aggregation database (gnomAD) that is devoid of individuals with severe pediatric disease, as well as their first-degree relatives 21 . Unlike the disease-associated R325W mutant, which induced changes in both channel activation and inactivation, the R325Q variant did not exhibit any significant changes in the properties analyzed, and thus behaved like the WT channel (Fig. 4A-B) .
Another variant S457R was classified as non-pathogenic based on inheritance from an unaffected parent and presence of this S457R as a singleton variant (MAF 3.983 e-06 ) in gnomAD 21 . In the homomeric configuration, S457R did not differ from WT on any measured parameters, although there was a hyperpolarizing shift in the voltage-dependence of activation in the co-expressed configuration.
S457 is subject to post-translational modification by phosphorylation, and dephosphorylation of KV2.1 is associated with hyperpolarizing shifts in voltage-dependent gating. 29 Thus, the observed difference in voltage-dependence of activation may reflect differences in phosphorylation state between the mutant (i.e. non-phosphorylated residue 457) and WT subunits (i.e. phosphorylated residue 457) under our experimental conditions, which require intracellular sodium fluoride, a known phosphatase inhibitor, for gigaohm seal formation.
Expression analysis of K V 2.1 variants: cell-surface trafficking
Presence at the cell-surface is critical for voltage-gated ion channel function, and some variants may interfere with efficient cell-surface expression of KV2.1 protein. Cell-surface and total expression levels of KV2.1 protein were simultaneously examined using immunocytochemistry followed by flow cytometry (FC). An extracellular HA epitope tag enabled discrimination of cell surface and total KV2.1 fractions allowing for rapid detection of pathogenic variants with deficient cell-surface expression. A substantial population of WT KV2.1 reached the cell-surface, with a mean surface/total expression ratio higher than 0.8, indicating highly efficient trafficking of KV2.1 to the cell-surface (Fig. 3A-B) , as previously shown for KV2.1 in other experimental models 30, 31 . The majority of the variants (13/19) exhibited pronounced deficits in cell-surface expression of KV2.1 protein (Fig. 5A-B) , potentially explaining the loss of K + conductance observed from high-throughput electrophysiology screening (Fig.   3C ). The non-pathogenic variants, R325Q and S457R, exhibited cell-surface and total expression that was indistinguishable from WT ( Fig. 5A-C) . Cross-validation of select variants (T210K/M, R312C, R325Q/W, V378A, and K391N) with cell-surface biotinylation followed by immunoblotting produced congruent results (Supplementary Fig. 2A-C) .
The S202F variant located near the HA-epitope insertion site (a.a.220) likely had altered immunoreactivity considering the lack of anti-HA signal but intact peak current density of S202F. It is possible that S202F results in steric hindrance caused by the substituted phenylalanine, preventing the HA antigen-antibody interaction (Supplementary Fig. 2D ). For the T210K/M variants, also located nearby the HA-tag insertion site, immunoblot analyses of the non-tagged T210K/M variants confirmed the reduced cell-surface expression by flow cytometry ( Supplementary Fig. 2 and Fig. 5A-B) , which is consistent with their loss-of-function phenotypes in homomeric configuration (Fig. 3A) .
The two truncation variants, Y274fsX36 and Y533X, were also tested for expression level analyses, despite lacking the epitope site for anti-Kv2.1-Alexa647 (a.a. 837-853 at C-terminus). The (Fig. 5D right) , indicating that truncated Y533X proteins reach the cell-surface.
Multivariate transformational analyses of K V 2.1 variants
To visualize the relationship among various parameters measured in this study, we performed principal component analyses using a total of 6 variables measured for the homomeric configuration: Ipeak density, V1/2 and k for activation and inactivation, protein expression cell-surface/total ratio (Fig. 6 ). The top 3 leading dimensions for PC1 were Ipeak density (0.61), cell-surface protein/total ratio (0.62), and V1/2 for activation (-0.28); and for PC2 were Ipeak density (0.62), and inactivation V1/2 (0.47) and k (0.49). Plotting PC1 vs. PC2 separated the nonpathogenic group (R325Q/S457R and WT; in green) from the pathogenic variants with 95% confidence. However, it was not possible to separate the pathogenic variants by clinical classification.
DISCUSSION K V 2.1 loss-of-function in KCNB1 DEE
Here we report high-throughput functional studies of 19 KCNB1 variants, including 17 likely pathogenic variants identified in individuals who underwent clinical genetic testing for epileptic encephalopathy and/or global DD or ID of unknown cause, as well as two presumed non-pathogenic variants present in the gnomAD population database that excludes individuals with severe pediatric disease 21 . Highthroughput electrophysiological and biochemical analysis of KV2.1 currents in cells transiently expressing these variants revealed partial or near-complete loss-of-function as a common feature, consistent with previous reports using manual electrophysiology on a limited number of KCNB1 variants [7] [8] [9] . The molecular mechanisms underlying loss-of-function phenotypes included lower peak current density due to low total and/or cell surface protein expression, as well as shifts in voltagedependence of activation and inactivation.
The majority of variants exhibited significantly lower peak current density when expressed as homotetramers. However, for many of those variants, co-expression with WT subunits normalized peak current density. Rescue by the presence of WT subunits suggest that variant subunits traffic to the cell surface as part of a heteromeric assembly, which raises the possibility for phenotypic rescue by molecular chaperones. In contrast, co-expression of some variants (R306C, V378L) with WT resulted in lower current density that was similar in magnitude to 0.5x WT, suggesting that while the mutant subunits cannot be rescued functionally, they do not interfere with cell surface expression of WT. Other variants (W370R, P385T, F416L) when co-expressed with WT exhibited lower current density than 0.5x WT, suggesting a potential dominant negative effect on cell surface expression of WT subunits.
Several variants encoded functional KV2.1 channels with current density indistinguishable from WT in the homotetramer configuration, but exhibited defects in voltage-dependence. Depolarizing shifts in V1/2 for both activation and inactivation were observed for S202F and R312H, resulting in loss-offunction due to impaired channel opening in a physiological voltage range. Conversely, R325W had hyperpolarized shifts in V1/2 for activation and inactivation. Although this likely results in enhanced channel opening at physiological voltages, the corresponding shift in the voltage-dependence of inactivation limits channel availability in the voltage range where KV2.1 normally operates, suggesting overall loss-of-function. Co-expression of WT channels to approximate heterozygosity resulted in attenuated or altered voltage-dependence. This may be explained by variable populations of WT+WT, WT+var, and var+var channels. The presence of significant voltage-dependence phenotypes that were specific to co-expression conditions (i.e. activation k for WT+S202F or activation V1/2 for WT+S457R)
suggests that for at least some variants, WT and variant subunits co-assemble in heterotetrameric channels.
Comparison of same site variable substitutions
The importance of experimental validation for individual variants is highlighted by pairwise comparison of substitutions of different amino acids at the same position (i.e. T210K/M, R312C/H, R325Q/W and V378A/L). The T210K/M (CADD score of 28.1 and 28.2, respectively) variants resulted in severe loss of K + conductance and cell-surface KV2.1 expression. Threonine 210 has been shown to be a critical residue forming the S1-pore interface and mutation of the corresponding position in other KV channels resulted in no detectable current 32, 33 . A hydroxyl group has been shown to be required at this position for channel function 33 . Thus, substitution with either lysine or methionine would be incompatible with S1-pore coupling and channel function. In contrast, R312H and R312C resulted in partial and severe lossof-conductance, respectively, which was the opposite of the in silico consequence prediction that suggested R312H (CADD score of 32) would be more deleterious than R312C (CADD score of 28.3). . Conversely, substitution with the smaller alanine has been shown to disrupt ion selectivity and may interfere with KV2.1 channel stability 36 . Previous studies of the V378A variant in CHO-K1 and COS-7 cells showed impaired expression that could be rescued by application of the KV2 inhibitor GxTx, suggesting enhanced internalization and degradation as a possible mechanism underlying deficient expression 9 . Consistent with this, we observed robust total expression of V378A at 24 hours post-transfection by immunocytochemistry/flow-cytometry (Fig. 5) , while immunoblotting at 72 hours showed little V378A expression (Fig S2) .
High-throughput variant characterization pipeline
One of the goals of this study was to leverage new electroporation and automated planar patch clamp technologies to develop a high-throughput pipeline for functional and biochemical characterization of KCNB1 variants identified by clinical genetic testing. With this optimized pipeline, it is feasible to functionally characterize new variants rapidly. Moreover, the immunocytochemistry-flow-cytometry assay developed here enables high-throughput detection of cell-surface and total protein expression levels for further delineation of the mechanisms by which a variant affects channel function. Efficient performance of functional and biochemical studies of ion channel variants is a critical step to realize the precision medicine goal of rapid, definitive precision diagnosis and eventually targeted treatment based on the individual's specific genetic variant.
Utility of functional characterization for clinical genetic testing
Based on ACMG guidelines, evidence of a deleterious effect on protein function can be considered as 'strong' evidence for pathogenicity, given that the functional assay is robust and validated 3 .
Electrophysiology is considered the gold standard for characterizing the effects of ion channel variants, and is a well-validated, robust approach. In contrast, in silico evidence based on pathogenicity prediction algorithms such as CADD, M-CAP, or others are only considered 'supporting' evidence, thus insufficient when considered alone. Functional variant characterization, both in channelopathies and other disorders, has untapped potential to provide significant diagnostic benefit for determining whether a particular variant is likely pathogenic. Our goal with KCNB1 is to functionally characterize a large series of variants to serve as a reference dataset for clinical genetic test interpretation in newly diagnosed patients, and to provide additional evidence for potential re-classification of variants previously classified as variants of uncertain significance.
The KCNB1 variants R325Q and S457R described herein provide a concrete example of how functional variant characterization can provide useful diagnostic information. R325Q is a rare population variant that exhibited similar functional characteristics to WT channels, suggesting that arginine 325 is a residue tolerant to substitution with glutamine (Q). However, R325W has significant functional defects both as a homotetramer and when co-expressed with WT (Fig. 3A&B) , suggesting this variant is likely pathogenic. Further strengthening the case for functional characterization, in silico pathogenicity predictions such as CADD scores actually predicted the opposite, with R325Q predicted as pathogenic (CADD=20.2) and R325W as likely benign (CADD=15.8). Another example concerns S457R, which was initially identified by clinical genetic testing in a child with DD and epilepsy and was later found upon parental testing to be inherited from an unaffected parent. Prior to parental testing, we performed an electrophysiological study of S457R in the homomeric configuration and found no deleterious effect on protein function, suggesting that this variant was non-pathogenic. Principal component analysis using measured parameters from the functional studies allowed reliable separation of nonpathogenic group, consisting of R325Q and S457R variants along with the WT, from the other 17 variants studied, highlighting the viability of high-throughput functional screening to differentiate nonpathogenic from pathogenic variants with high confidence (95%).
Limitations of high-throughput functional screening
Despite the aforementioned strengths of high-throughput screening of genetic variants in a heterologous expression model, there are some limitations. Some of the KV2.1 variant effects detected in our study may become less or more pronounced in neurons, as neurons are highly specialized cells with diverse distinct morphologies compared to CHO cells. For example, variant and WT alleles are co-expressed in individuals with KCNB1 DEE, which is associated with heterozygous variants. However, in the heterologous expression system, co-expression with WT sometimes masked variant effects. This highlights a difference between heterologous expression versus the nervous system, and suggests that homomeric expression provides a more robust assay. In addition, conducting K + is not the only function of KV2.1 in neurons, as a population of non-conducting KV2.1 clustered at plasma membrane-endoplasmic reticulum junctions operate as a docking site for membrane proteins 31 . Lastly, for variants that alter binding site affinity for interacting proteins like KChAP, AMIGO, and KCNE1-3 [37] [38] [39] , their effect may not be detected if these proteins are not present at physiological levels in this model. Hence, additional characterization of variants in more complex experimental systems such as knock-in mice or patient-derived iPSCs may be needed for more complete understanding of disease mechanisms in neurons or other cells where KV2.1 is a significant contributor (e.g., pancreatic beta cells).
Another goal of our study was to assess potential correlations between KV2.1 channel dysfunction and clinical severity. We used principal component analysis to address this question using 6 parameters that were measured experimentally. Although the clinical phenotypes of DEE and NDD were not distinguished, it is possible that the NDD cases (3-6 years of age at the time of reporting) will go on to develop epilepsy, as there are at least two DEE cases with seizure onset in adolescence (Table 1) .
Alternatively, the underlying pathogenic mechanisms may require more complex experimental systems like neurons or in vivo animal models, and/or that final expression of the clinical phenotype can be influenced by other genetic, epigenetic or environmental modifiers.
Conclusions
In summary, many of the disease-associated KCNB1 variants (14/17) we studied exhibit loss-of-function phenotypes that ultimately result in a channel hypofunction, through 1) decreased K + conductance, 2) altered voltage-dependence of channel activation or inactivation, 3) reduced protein expression, or 4) altered cell-surface trafficking. Classification of KCNB1 variants into different categories of defects indicates that molecular chaperones to increase cell-surface expression may be a suitable therapeutic strategy for some patients. A subtype-selective activator of KV2.1 may be a viable therapy for others, although this would not address non-conducting functions of KV2.1 31, 40 , which may contribute to disease pathophysiology. Alternatively, gene therapy approaches that increase expression of the WT allele may hold promise for treatment of patients with KCNB1 variants. It is thus critical to be able to efficiently and reliably characterize KCNB1 variants in patients with DEE or DD/ID as pathogenic to provide the precision diagnoses required for precision treatment. 
variants
Experimental data for biophysical and protein expression analyses were transformed with respect to WT, to generate eigenvector-based multivariate analyses, and plotted using ClustVis 20 . Nipals PCA is used to calculate principal components, with ellipses depicting 95% confidence interval. Each axes explains 61% and 24.1% of the total variance (X and Y, in order): N = 20 data points. Total of 6 variables measured in the homomeric condition were used: Ipeak density, V1/2 and k for activation and inactivation, protein expression cell-surface/total ratio. The top 3 leading dimensions (variable) for PC1 were Ipeak density (0.61), cell-surface/total expression ratio (0.62), V1/2 for activation (-0.28); and for PC2 were Ipeak density (0.62), and inactivation V1/2 (0.47) and k (0.49). Nonpathogenic variants and WT (in green) are separable from the pathogenic variants (red, blue). DEE, developmental epileptic encephalopathy; NDD, neurodevelopmental disorder.
